


LONG SHELF-LIFE  $^{99m}\text{Tc}$ -MAA LUNG PARTICLE KITS

Although a welcome innovation, the "instant"  $^{99m}\text{Tc}$ -MAA kit preparation as described in the literature (1,2) proved to have two disadvantages when performed in this and another laboratory (3).

First, the particles are not actually preformed but must be adjusted before injection by ramming them through a small bore needle. This both necessitates microscopic assay and creates a broad particle distribution range. Second, the refrigerated particles aggregate with time and become difficult to size suitably for injection.



**FIG. 1.** (A) Particles produced without surfactant after being stored at 4°C for 2 weeks. (B) Heterogenous array of particles produced after ramming particles shown in (A) through small bore needle. (C) Particles at time of production using surfactant. (D) Same particles as in (C) after 4 months storage at 4°C. (No differences were noted in clinical image quality when using particles ranging from 1 day to 4 months after production.) (E) Same particles as in (C) after 1 month frozen storage. (F) Reconstituted particles produced with surfactant after lyophilization.

These disadvantages can be remedied by adding a small amount of nonionic surfactant, polysorbate-80 USP, to the preparation. This affords a 100% preformed particle stable for more than 4 months, comparable tissue distribution and biological half-times with those described (1), and decreased sensitivity of agitation and thermal incubation steps, resulting in greater batch reproducibility.

To produce the particles, a 30-ml vial containing a 1-in. bar magnet is affixed to a rectangular-based stand on top of an inexpensive, immersible, pneumatic stirrer. Five milliliters of a 1.0% HSA and 10% sodium acetate solution along with 19 ml water for injection are aseptically transferred into the vial. After these solutions are mixed, 1.0 ml of 0.5% stannous chloride in 1.0 N HCl is added. This solution is mixed for 2 min, after which 1.5 ml of 10% polysorbate-80 solution is added.

The stand is then lowered into a constant-temperature water bath ( $80 \pm 1^\circ\text{C}$ ) until one-fifth of the vial is immersed. The solution is stirred at maximum for 12 min. The stand is removed and the particles mixed for 5 min more.

The particles are assessed and dispensed in 1-ml lots into 10-ml sterile vacutainer tubes. These tubes are then refrigerated (the most convenient), frozen, or lyophilized before use. The particles should be both macro- and microscopically examined until the investigator has documented his particle preparation for stability and particle reproducibility.

To label the refrigerated particles, add from 10–20 mCi  $^{99m}\text{Tc}$ -pertechnetate solution. Shake particle solution for 30 sec before administration.

JOHN P. HUBERTY  
Department of Radiology  
University of California  
San Francisco, California

REFERENCES

1. SUBRAMANIAN G, ARNOLD RW, THOMAS FD, et al: Evaluation of an instant  $^{99m}\text{Tc}$ -labeled lung scanning agent. *J Nucl Med* 13: 790, 1972
2. SUBRAMANIAN G:  *$^{99m}\text{Tc}$  Labeled Radiopharmaceuticals a Compilation of Procedures*. Syracuse, NY, Upstate Medical Center
3. COLE C: Presidio, San Francisco, Calif, Letterman General Hospital, 1973: Personal communication